PDF(Pubmed)
Abstract：
Research is increasingly revealing that inflammation significantly contributes to various diseases, particularly inflammatory bowel disease (IBD). IBD is a major medical challenge due to its chronic nature, affecting at least one in a thousand individuals in many Western countries, with rising incidence in developing nations. Historically, indigenous people have used natural products to treat ailments, including IBD. Ethnobotanically guided studies have shown that plant-derived extracts and compounds effectively modulate immune responses and reduce inflammation. Similarly, helminths and their products offer unique mechanisms to modulate host immunity and alleviate inflammatory responses. This review explored the pharmaceutical potential of Aboriginal remedial plants and helminths for treating IBD, emphasizing recent advances in discovering anti-inflammatory small-molecule drug leads. The literature from Scopus, MEDLINE Ovid, PubMed, Google Scholar, and Web of Science was retrieved using keywords such as natural product, small molecule, cytokines, remedial plants, and helminths. This review identified 55 important Aboriginal medicinal plants and 9 helminth species that have been studied for their anti-inflammatory properties using animal models and in vitro cell assays. For example, curcumin, berberine, and triptolide, which have been isolated from plants; and the excretory-secretory products and their protein, which have been collected from helminths, have demonstrated anti-inflammatory activity with lower toxicity and fewer side effects. High-throughput screening, molecular docking, artificial intelligence, and machine learning have been engaged in compound identification, while clustered regularly interspaced short palindromic repeats (CRISPR) gene editing and RNA sequencing have been employed to understand molecular interactions and regulations. While there is potential for pharmaceutical application of Aboriginal medicinal plants and gastrointestinal parasites in treating IBD, there is an urgent need to qualify these plant and helminth therapies through reproducible clinical and mechanistic studies.
摘要：
越来越多的研究表明，炎症会导致各种疾病，特别是炎症性肠病（IBD）。IBD由于其慢性性质，是一个重大的医学挑战，在许多西方国家，千分之一的人受到影响，随着发展中国家发病率的上升。历史上,土著人使用天然产品来治疗疾病，包括IBD。民族植物学指导的研究表明，植物来源的提取物和化合物可有效调节免疫反应并减少炎症。同样，蠕虫及其产品提供了独特的机制来调节宿主免疫和减轻炎症反应。这篇综述探讨了土著补救植物和蠕虫治疗IBD的药物潜力，强调发现抗炎小分子药物导联的最新进展。Scopus的文学作品,MEDLINEOvid,PubMed,谷歌学者，WebofScience是使用诸如天然产品之类的关键字检索的，小分子,细胞因子,补救植物，还有蠕虫.这篇综述鉴定了55种重要的原住民药用植物和9种蠕虫物种，这些物种已使用动物模型和体外细胞测定法研究了它们的抗炎特性。例如,姜黄素,小檗碱,和雷公藤甲素,从植物中分离出的排泄分泌产物及其蛋白质，从蠕虫中收集的，具有较低毒性和较少副作用的抗炎活性。高通量筛选，分子对接,人工智能,和机器学习已经从事复合识别，而成簇的规则间隔短回文重复（CRISPR）基因编辑和RNA测序已被用于了解分子相互作用和调控。虽然土著药用植物和胃肠道寄生虫在治疗IBD方面有药物应用的潜力，迫切需要通过可重复的临床和机理研究来鉴定这些植物和蠕虫疗法。
